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Abstract
Background: Several scan parameters for PET imaging with 18F-PSMA-11 such as dosage, acquisition time and scan
duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide
administration on lesion visualization. Forty-four patients were randomly assigned to a dosage group (2.0 ± 0.2 or
4.0 ± 0.4 MBq/kg 18F-PSMA-11). All patients received a full-body PET/CT 1 h and 3 h after radiotracer injection with a
scan duration of 3 min/bed position. For comparison of the scan duration, images were reconstructed for 1.5 and 3
min/bed position. Patients were intravenously administered 0.5 mg/kg furosemide with a maximum dose of 40 mg.
To evaluate the furosemide effect, 22 additional patients were recruited and received one full-body PET/CT 1 h after
administration of 2.0 ± 0.2 MBq/kg 18F-PSMA-11 with a scan duration of 3 min/bed position. To this group, no
furosemide was administered. Images were scored on image quality using a 7-point scale and each suspicious
lesion was described. To assess interrater reliability, two nuclear physicians scored all scans independently and
described all observed suspicious lesions.
Results: The 4 MBq/kg group received for all reconstructed images (60 min p.i., 1.5 and 3 min/bed position and 180
min p.i., 1.5 and 3 min/bed position) the highest median image quality score compared to the 2 MBq/kg group
(p values < 0.01). When comparing all reconstructed images, the highest image quality score was given to images
at 60 min p.i., 3 min/bed position for both dosage groups (score 5 and 6 for 2 and 4 MBq/kg, respectively). The
addition of furosemide administration decreased the interference score with one point (p = 0.01106) and facilitated
the evaluation of lesions in proximity to the ureters. The interrater reliability for the comparison of each lesion
separately after more than 40 18F-PSMA-11 scan readings showed an increasing κ value from 0.78 (95% CI, 0.65–
0.92) to 0.94 (95% CI, 0.87–1).
Conclusion: Although the results indicate an administered activity of 4.0 ± 0.4 MBq/kg, preference will be given to
2.0 ± 0.2 MBq/kg due to the small difference in absolute score (max 1 point) and the ALARA principle. For
evaluation of lesions in proximity to the ureters, the co-administration of a diuretic can be useful. The increase of
the κ value from 0.78 to 0.94 suggests a learning curve in the interpretation of 18F-PSMA-11 images.
Trial registration: Clinicaltrials.gov, NCT03573011. Retrospectively registered 28 June 2018
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Introduction
In recent years, prostate-specific membrane antigen
(PSMA) has been the most widely studied target for im-
aging of recurrent and metastatic prostate cancer. 18F-
PSMA-11, a fluorine-18 derivative of the frequently used
68Ga-PSMA-11 PET radiotracer, was developed [1, 2],
automatized [3] and evaluated for safety, biodistribution
and dosimetry in a previously published study [4]. Before
comparing the clinical efficacy of 18F-PSMA-11 to other
PSMA tracers, a Phase 2 trial should be conducted to
determine the scan protocol which will be applied in
following studies and clinical practice. Phase 2 trial de-
signs are usually exploratory where multiple scan param-
eters are tested to determine the optimal scan protocol.
These parameters include radiotracer dosage, start of
PET acquisition post injection, scan duration, image re-
construction parameters and updating the safety data-
base. This requires the selection of the appropriate
patient population. Finally, the variability between ob-
servers should be evaluated as the correct interpretation
of PET images is a crucial step in the validation of the
clinical efficacy of 18F-PSMA-11 and should lead to the
development of criteria for image evaluation. The opti-
mized scan protocol can then be applied in Phase 3 clin-
ical trials to obtain data necessary for approval for
application of the radiotracer in clinical use. In these lar-
ger studies, it is possible to evaluate the effect of the spe-
cific activity and the radionuclide on image quality, as
well as the amount of nonradioactive ligand and carrier
[5, 6]. The aim of this study was to determine the opti-
mal scan protocol with regard to radiotracer dosage, ac-
quisition time and duration and co-administration of
furosemide. As a secondary objective, the interrater reli-
ability was assessed.
Materials and methods
All procedures performed in this study involving human
participants were in accordance with the ethical standards
of the Ethics Committee of the Ghent University Hospital
(2017/1294) and with the 1964 Helsinki Declaration and
its later amendments or comparable ethical standards
(EudraCT nr, 2017-003461-96). The study was supported
by the Flemish Foundation FWO TBM (T001517).
Patients
In total, 66 patients (age 46–84 years, median 70.5) with
primary staging or biochemical recurrence after curative
treatment (prostatectomy with or without lymphadenec-
tomy or radiotherapy) were prospectively included
during a consultation with their treating physician. Pa-
tients who were under the age of 18 years old, who re-
fused to be informed about accidental findings on scans
and who were physically or mentally unfit to perform
the sequential procedures were excluded from the trial,
as well as patients suffering from heart failure with an
ejection fraction < 45% and patients with a known his-
tory of anaphylactic shock after administration of CT
contrast. Written, dated and signed informed consent
was obtained from all patients before any trial-related
procedures were conducted. In total, four patients
dropped out of the study.
Safety monitoring
All adverse events were actively monitored from time of
radiotracer injection until completion of the second
PET/CT scan and reported according to the CTCAE 4.0
scoring system. Although there was only one patient
with an increased creatinine level in the previously con-
ducted Phase 1 study, we deemed it useful to further
evaluate the creatinine level changes before and after ra-
diotracer injection in Phase 2. Therefore, a 3-mL blood
sample was taken and compared to the latest available
creatinine lab value before inclusion in the study.
Study protocol
Randomization was performed using a block design with
variable block sizes of two, four, and six. The first 44
patients were randomly assigned to either of the two
dosage groups, 2.0 ± 0.2 MBq or 4.0 ± 0.4 MBq 18F-
PSMA-11 per kilogram body weight. The overview of all
performed study procedures is summarized in Fig. 1.
Thirty minutes after receiving the appropriate dosage,
each patient was given an intravenous bolus injection of
0.5 mg/kg body weight furosemide with a maximum
dose of 40 mg to improve diuresis. Two whole-body PET
scans were acquired at 60 ± 5min (T60) and 180 ± 5
min (T180) post injection (p.i.) and 3 min per bed pos-
ition (bp). The first PET scan was preceded by a diag-
nostic CT scan with administration of Visipaque® CT
contrast, the second PET scan was preceded by a low-
dose CT scan for attenuation correction. To evaluate the
effect of furosemide on the image quality, 22 additional
patients were recruited who received only one PET scan
60 ± 5min after administration of 2.0 ± 0.2 MBq/kg 18F-
PSMA-11 accompanied by a diagnostic CT scan. This
group received no furosemide. PET/CT imaging was
performed using a GE Discovery MI 3-ring system, a
digital PET/CT scanner with SiPM-based PET detectors
coupled to Luthetium-based scintillators, a measured
resolution of around 4.5 mm and an axial field of view of
15 cm. Reconstruction of the PET scans was performed
using the QClear algorithm (GE Healthcare), a block
sequential regularized expectation-maximization algo-
rithm. The reconstruction includes time-of-flight infor-
mation (resolution of 290 ps FWHM), point spread
function compensation, CT-based attenuation and scat-
ter correction and a beta-parameter of 600. Each PET
image was reconstructed for emission times of 1.5 min/
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bp and 3min/bp to evaluate the effect of the scan dur-
ation. The individual characteristics of patients who com-
pleted all described procedures are presented in Table 1.
Chi-square and one-way ANOVA was performed for cat-
egorical and continuous variables, respectively. Patient
characteristics such as weight and previous undergone
procedures and therapies were not accounted for in the
comparison as the aim of this study was to provide a
general recommendation for 18F-PSMA-11 imaging.
(Semi-)quantitative analysis of dosage and acquisition
times
A nuclear physician scored each scan on the image qual-
ity using a 7-point scale (1 = very poor image quality, 7
Fig. 1 Flowchart of the study procedures
Table 1 Patient characteristics of patients who completed all planned procedures. Chi-square and one-way ANOVA was performed
for categorical and continuous variables, respectively
2.0 ± 0.2 MBq/kg
with furosemide
2.0 ± 0.2 MBq/kg
without furosemide
4.0 ± 0.4 MBq/kg
with furosemide
Number of patients 21 21 20
Age (median, Q1–Q3) 71 (65–74) 70.5 (63.5–77.25) 69 (63–74) F(2,59) = 0.149, p = 0.862
Weight (mean ± SD) 85.1 ± 14.4 80.9 ± 10.9 81.5 ± 11.9 F(2,59) = 0.691, p = 0.505
Staging Χ2(2, N = 62) = 6.6633, p = 0.03573
Initial staging 0/21 6/21 4/20
Restaging 21/21 15/21 16/20
PSA (ng/mL) (mean ± SD) 6.90 ± 9.89 9.22 ± 18.38 7.35 ± 10.96 F(2,59) = 0.161, p = 0.851
Gleason score Χ2(4, N = 62) = 2.8402, p = 0.5849
≤ 7 8/21 8/21 9/20
8 4/21 8/21 5/20
≥ 9 9/21 5/21 6/20
Previous treatment Χ2(8, N = 62) = 6.7322, p = 0.5658
Prostatectomy
Salvage therapy 13/21 12/21 10/20
Definitive 13/21 9/21 5/20
Radiotherapy 6/21 3/21 7/20
Current ADT 8/21 3/21 2/20
Chemotherapy 1/21 1/21 0/20
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= exceptional image quality) with the assumption of
equal distances between each point. The score was based
on the ability to distinguish lesions from the back-
ground. Lesions were determined based on concordance
of findings with CT images and gained experience. To
assess the different dosages, image quality scores were
compared between the two dosage groups. To determine
the optimal acquisition time and duration, the image
quality score and lesion detection of patients who pre-
sented with less than 10 suspicious lesions were evalu-
ated within each dosage group. This restriction was
included to avoid disproportional impact of patients with
multiple lesions on the overall result. The percentage
agreement was calculated using the images at T60, 3
min/bp as the reference. Finally, the relative contrast
noise ratio (CNR) was determined for all suspicious
lesions observed within the 2MBq/kg group. The rela-
tive CNR is equal to the ratio of the relative contrast
and relative noise, which are calculated using Eq. 1 and
2, respectively. Relative CNR values of T60, 3 min/bp
images will be compared to relative CNR values of T60,
1.5 min/bp and T180, 3 min/bp images to evaluate the
effect on lesion visualization of acquisition duration and
time, respectively.
relative contrast ¼ SUVpeak L−SUVmean B
SUVpeak L
Equation 1: Calculation of relative contrast with SUV
= standardized uptake value, L = suspicious lesion and B
= 10mm bulb shell around the suspicious lesion
relative noise ¼ standard deviationH
meanH
Equation 2: Calculation of relative noise with H =
spherical region (r = 2 cm) in proximity of the suspicious
lesion
Evaluation of co-administration of furosemide
Because 18F-PSMA-11 shows a high urinary clearance
(29.0 ± 5.9% 300min p.i.) [4], a diuretic (furosemide) was
added to the study protocol to reduce interference of the
ureters on the PET image. To assess the effect of fur-
osemide on the image quality, 22 additional patients
were recruited. The PET images were compared to the
initial 22 patients who underwent the same scan proto-
col with administration of furosemide. The interference
of the radioactivity uptake in the bladder and the ureters
on the interpretation of the scan was evaluated on a 7-
point scale (1 = not disturbing, 7 = very disturbing) with
the assumption of equal distances between each point.
Interrater reliability
To evaluate the variability in the interpretation of de-
tected suspicious lesions on the PET scans, two inde-
pendent observers who were blind for dosage group but
with access to the medical history assessed each PET/
CT scan. Both observers had at least 4 years clinical ex-
perience as nuclear physicians and had evaluated 18F-
PSMA-11 scans in the previously conducted Phase 1
trial. No previous study-related training in PSMA image
readings was given and there was no study-related com-
munication between the two observers during the data
handling. The interrater reliability was evaluated based
on images of the preferred scan time and duration. Each
nuclear physician appointed the patients to one of
following disease status: no tumour, local disease, locor-
egional disease, oligo- (0–3 suspicious lesions) or poly-
metastatic (≥ 4 suspicious lesions) disease. Observed
suspicious lesions were described and subdivided into
the following locations: prostatic, lymphatic, bone or vis-
ceral metastasis. When patients presented with more
than 10 suspicious lesions, no description of the lesions
was performed and these results were therefore not in-
cluded in the analysis. The interrater reliability was
based on concordance of disease status, the total number
of suspicious lesions per location and agreement on each
suspicious lesion separately. To determine if a learning
curve is applicable to the reliable interpretation of im-
ages, all analyses were performed on the predetermined
optimal scan protocol for both the initial and the later
conducted extended Phase 2 study.
Statistical analysis
All statistical analyses were performed using R software
[7]. For comparison of ordinal data between the two
groups (comparison of dosage groups, evaluation of the
effect of furosemide), the Mann-Whitney U test was per-
formed. For the detection of a difference between > 2
paired groups (comparison of four timeframes: T60, 1.5
and 3min/bp, and T180, 1.5 and 3min/bp), a pairwise
Wilcoxon signed-rank test corrected for multiple testing
(Bonferroni-Holm correction [8]) was performed. How-
ever, the difference in image quality was only considered
clinically relevant when the difference in median value
was more than 1 point. κ statistics and 95% confidence
intervals were calculated using the ‘psych’ package [9] to
evaluate the interrater reliability. The κ values were
interpreted according to the categories presented in
Table 2 [10]. The significance level for all tests was set
on α = 0.05.
Results
Administration of 18F-PSMA-11
Synthesis of 18F-PSMA-11 was performed as described
by Kersemans et al. [3]. The radiochemical purity was
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determined using high-performance liquid chromatog-
raphy and thin-layer chromatography and exceeded 98%
and 96%, respectively. Of the initial 44 patients included,
41 patients completed the study protocol of which 21
and 20 subjects were part of the 2 and 4MBq/kg group,
respectively. Of the 22 patients recruited in the add-
itional Phase 2, 21 patients completed the study proto-
col. Patients of the 2MBq/kg and 4MBq/kg group were
administered 167 ± 29MBq 18F-PSMA-11 (4.2 ± 2.4 μg
PSMA-11) and 313 ± 56MBq 18F-PSMA-11 (8.3 ± 4.1 μg
PSMA-11), respectively. Patients of the additional Phase
2 study were administered 161 ± 23MBq 18F-PSMA-11
(7.3 ± 3.8 μg PSMA-11). Except for one patient who suf-
fered from an allergic cutaneous reaction at the palms
(grade 2 CTCAE; likely related to the CT contrast Visi-
paque®), none of the patients reported any subjective
side effects. Creatinine level changes showed a wide vari-
ability with an average change in serum creatinine levels
of 1.67% ± 10.67%.
Optimisation of scan protocol
The median and interquartile range (IQR) of the image
quality scores are presented in Table 3 with p values
evaluating the difference between the dosage groups for
each time frame. The median scores of the 4MBq/kg
were 1 point higher (T60, 1.5 and 3min/bp and T180,
1.5 min/bp) or equal (T180, 3 min/bp) to the 2MBq/kg
group (Fig. 2). All p values were below the significance
level of 0.05. However, the difference in median scores
between the dosage groups did not exceed the clinically
relevant difference of > 1 point. A detailed overview of
the results can be found in the Additional file 1.
For the evaluation of the optimal scan time (T60 vs
T180) and scan duration (1.5 versus 3 min/bp), all sets
of reconstructed images were compared to one another
within each dosage group. In general, most images at
T180 showed high background noise and were difficult
to read (Fig. 3). The images at T60, 3 min/bp showed
the highest median image quality score in both dosage
groups (5 and 6 for 2 and 5MBq/kg, respectively).
Table 4 shows that the pairwise comparison of the image
quality scores between all sets of reconstructed images
was significantly different from each other for both dos-
age groups (p values < 0.05). This suggested that imaging
60min p.i. for 3 min per bed position provides the best
image quality. Pairwise comparison of suspicious lesions
between all sets of reconstructed images only showed a
significant difference in the 2MBq/kg group between
T180, 1.5 min/bp images and all other scan times
(Table 5). The percentage agreement between suspicious
lesions detected on the reference scan T60, 3 min/bp for
2 and 4MBq/kg and comparison scans were 90.5% and
96.9% for the T60, 1.5 min/bp scan, 42.9% and 61.5% for
the T180, 1.5 min/bp scan and 71.4% and 60% for the
T180, 3 min/bp scan, respectively. The relative CNR of
corresponding suspicious lesions of 2MBq/kg images on
T60 between 1.5 min/bp and 3min/bp increased 16.4%
(95% CI, 11.3–21.5). When comparing corresponding
suspicious lesions on T60, 3 min/bp and T180, 3 min/bp
images, the relative CNR decreased over time by 31.0%
(95% CI, 20.8–41.3). A comparative overview of repre-
sentative lesions between dosage groups and recon-
structed time frames is given in Figs. 4 and 5.
Evaluation of co-administration of furosemide
The median score of the interference on the bladder and
ureters was 2 (IQR = 0) for the furosemide group and 3
(IQR = 2) for the group without administration of fur-
osemide (p value of 0.01106 (< 0.05)). This suggests
slightly less interference when furosemide was adminis-
tered. Although statistically significant, the median dif-
ference of 1 is lower than the predetermined clinically
relevant difference of more than 1 point.
Evaluation of interrater reliability
All analysis was performed on the T60, 3 min/bp scans
of the 2MBq/kg group. When considering the agree-
ment in disease status (no tumour, local, locoregional,
oligo- or polymetastatic), the κ value of 0.92 (95% CI,
0.76–1) suggests an almost perfect interrater agreement.
For the ability to detect suspicious lesions reliably in the
most common metastatic regions (prostate, lymph
nodes, bone and viscera), an overall κ value of 0.90 (95%
Table 2 Determination of interpretation categories of kappa
values, adapted from Landis and Koch [10]
κ Level of agreement
< 0 Poor
0.00–0.20 Slight
0.21–0.40 Fair
0.41–0.60 Moderate
0.61–0.80 Substantial
0.81–1 Almost perfect
Table 3 Median, interquartile range (IQR) and p values of the
image quality scores of the 2 and 4 MBq/kg groups for sets of
reconstructed images (60 and 180 min p.i., 1.5 and 3min scan
time per bed position)
2 MBq/kg 4 MBq/kg p value
Median (IQR) Median (IQR)
T60, 1.5 min/bp 4 (0) 5 (1) 0.001132*
T60, 3 min/bp 5 (1) 6 (1) 0.007741*
T180, 1.5 min/bp 1 (1) 2 (0.5) 0.0007*
T180, 3 min/bp 3 (1) 3 (0.25) 0.001987*
*p values < 0.05 were considered statistically significant
bp bed position
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CI, 0.90–0.90) is found. The comparison of each lesion
separately gives a κ value of 0.78 (95% CI, 0.65–0.92)
which indicates a substantial agreement. To evaluate if
the interrater reliability increases after gaining experi-
ence, the same analyses were performed for the patients
of the extended Phase 2. The κ statistics for the agree-
ment in disease status, metastatic regions and lesions
separately were 1 (95% CI, 1–1), 0.98 (95% CI, 0.98–
0.98) and 0.94 (95% CI, 0.87–1). The comparison of the
results is presented in a forest plot (Fig. 6).
Discussion
An increased interest in PSMA-based radiotracers has
led to multiple clinical trials on PSMA PET imaging for
Fig. 2 Comparison of images at T60, 3 min/bed position of two patients NGP2-39 and NGP2-1 who received 2 and 4 MBq/kg, respectively.
NGP2-x = patient ID
Fig. 3 MIP images of patients NGP2-6 (2 MBq/kg, top) and NGP2-4 (4 MBq/kg, bottom). NGP2-x = patient ID
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prostate cancer [11–13]. To achieve an accurate and reli-
able image interpretation, a standardized scan protocol
is necessary for implementation in clinical practice [14].
This study determines the optimal scan protocol for
PET imaging of 18F-PSMA-11 by considering the effect
of activity dosage, acquisition time, scan duration and
furosemide co-administration on image quality and le-
sion detection.
Various dosage schemes have been proposed for
PSMA radiotracers. For 68Ga-PSMA-11, the joint guide-
lines of EANM and SNMMI recommend a dosage of
2.0 ± 0.2MBq/kg [14], while for 18F-PSMA-1007, dos-
ages up to 4MBq/kg are applied [15]. In this study, two
dosage groups (2 and 4MBq/kg body weight) were com-
pared. The administered activity is the primary factor
that determines the radiation exposure and should
therefore be kept as low as reasonably achievable
(ALARA principle) while minimizing the loss of diagnos-
tic information [16–18]. The higher dosage of 4MBq/kg
and associated increased radiation exposure will there-
fore only be tolerated when the difference in median
score between both dosage groups is more than 1 point,
as smaller differences will not be considered clinically
relevant. Although the median difference between the
two dosage groups was statistically significant, the > 1
point difference criterion was not achieved to accept the
4MBq/kg body weight as dosage. Therefore, 2.0 ± 0.2
MBq/kg body weight is recommended for achieving
images of sufficient quality while limiting the radiation
exposure. This is in agreement with the joint EANM
and SNMMI guidelines for PET/CT imaging with 68Ga-
PSMA [14]. For dosage optimization, inter-subject
comparison was not possible as this would imply admin-
istration of both doses to each patient, which would
unnecessarily increase patient radiation exposure. A
compromise for this limitation is the comparison of the
lesion detection of patients injected with 4MBq/kg be-
tween the short (1.5 min/bp) and long (3 min/bp) scan
time per bed position. One can argue that assuming lin-
earity of the PET camera, imaging at half the acquisition
time can simulate the administration of half the dosage.
As seen in Table 5, the p value of the comparison be-
tween T60, 1.5 and 3min and T180, 1.5 and 3min is
both times equal to 1, which confirms the recommenda-
tion of a dosage of 2MBq/kg 18F-PSMA-11.
Many studies have compared early and delayed scan-
ning; however, opposite results were obtained. Schmuck
et al. and Afshar-Oromieh et al. both found a higher
tumour-to-background ratio for some lesions on delayed
68Ga-PSMA-11 imaging but did not agree on the change
in overall detection rate [19, 20]. Rahbar et al. found no
additional benefit in delayed 68Ga-PSMA-11 acquisition
[21], while Derlin et al. showed an improved image qual-
ity for 68Ga-PSMA-I&T on delayed imaging but only
when combined with delayed furosemide administration
[22]. This shows that the acquisition time can be an im-
portant scan parameter but no consensus has yet been
reached on this topic. As the longer half-life of 18F
makes delayed imaging more accessible, it was deemed
appropriate to evaluate imaging 1 h and 3 h after 18F-
PSMA-11 administration. Images at T180 were more
difficult to read and there appears to be increased uptake
in the bone. However, a decrease in CNR was observed
over time. This suggests that either the uptake in sur-
rounding bone tissue increases and/or lesion uptake de-
creases. Additional analysis of the Phase 1 study [4]
showed that the activity in bone versus total body in-
creased with 10.86% from 90 to 300 min p.i. This in-
crease is probably partially caused by free 18F. However,
90 min p.i., less than 10% of the injected activity is
present in the blood of which only 22.2 ± 1.5% is free
18F-fluoride. This means that the amount of 18F-fluoride
in absolute quantity is low. Another contributing factor
could be slow tracer clearance from bone tissue, but this
should be further investigated. This observation corre-
sponds to a study by Afshar-Oromieh et al. who
Table 4 p values of the pairwise comparison of the image quality
scores within the 2 MBq/kg group and the 4MBq/kg group for all
sets of reconstructed images. p values < 0.05 were considered
statistically significant
T60, 1.5 min/bp T60, 3 min/bp T180, 1.5 min/bp
Image quality score 2 MBq/kg
T60, 3 min/bp 0.00038 – 0.00027
T180, 1.5 min/bp 0.00024 0.00027 –
T180, 3 min/bp 0.00074 0.00038 0.00047
Image quality score 4 MBq/kg
T60, 3 min/bp 0.00011 – 0.00026
T180, 1.5 min/bp 0.00026 0.00026 –
T180, 3 min/bp 0.00026 0.00025 0.00021
bp = bed position
Table 5 p values of the pairwise comparison of the lesion
detectability within the 2 MBq/kg group and the 4 MBq/kg
group for all sets of reconstructed images. p values < 0.05
were considered statistically significant
T60, 1.5 min/bp T60, 3 min/bp T180, 1.5 min/bp
Detection of suspicious lesions 2 MBq/kg
T60, 3 min/bp 1 – 0.0063
T180, 1.5 min/bp 0.0063 0.0063 –
T180, 3 min/bp 1 1 0.0063
Detection of suspicious lesions 4 MBq/kg
T60, 3 min/bp 1.00 – 0.17
T180, 1.5 min/bp 0.17 0.17 –
T180, 3 min/bp 0.21 0.21 1.00
bp = bed position
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evaluated additional late scanning with 68Ga-PSMA-11
[20]. Images at T60, 3 min/bp were given the highest
median image quality scores and were therefore chosen
as reference for following analyses. For the number of
detected suspicious lesions, only T180, 1.5 min/bp was
significantly inferior. Since only 42 lesions were detected
in 11 patients, the number of lesions might be too small
to detect a statistical difference between the other scan
images. A high percentage agreement was only found
between images at T60 (90.5%) while fewer lesions were
detected on images at T180. Although the total number
of detected suspicious lesions on T180, 3 min/bp were
initially similar to the reference scan (32 vs 34 lesions re-
spectively), retrospective analysis of the detected suspi-
cious lesions showed that the suspicion of certain bone
lesions was due to low image quality or aspecific uptake
because of degenerate bone disease, which reduced the
total number from 32 to 28. Finally, the relative CNR of
suspicious lesions increased for longer acquisition times
while decreasing when scanning occurred at a later time
point. Taking into account all the abovementioned re-
sults, imaging 60min p.i. with a scan duration of 3 min
per bed position was recommended, which is in accord-
ance to the joint EANM and SNMMI guidelines on im-
aging with 68Ga-PSMA [14]. However, despite the lower
image quality, the similar lesion detection rate of T60, 3
min/bp and T60, 1.5 min/bp would make the latter a
possible acquisition scheme when shorter acquisition
times are required. These results confirm similar previ-
ous findings by Goethals et al. [23] and Hausmann et al.
[24]. No evidence was found to recommend delayed im-
aging with 18F-PSMA-11 in our study. No dynamic
whole-body PET scans were performed for several rea-
sons. Firstly, the previously conducted Phase 1 study [4]
showed no increased uptake in major organs (except the
kidneys) or possible lesions between 50 and 90min p.i.
Also, a broad set of inclusion criteria was applied to ob-
tain a diverse cohort of patients in order to evaluate the
radiotracer for different disease stages and metastases lo-
cations. Therefore, the condition of many elderly pa-
tients did not allow for intensive dynamic imaging
protocols. Furthermore, the administration of a diuretic
prevented prolonged scan duration. Therefore, the study
protocol was limited to two acquisition times based on
previously reported results [4] and literature reporting
on scanning 60min p.i. and increased lesion detectability
180 min p.i [14, 25, 26]. Dynamic imaging will be further
investigated in ongoing animal experiments.
Furosemide co-administration reduced slightly the
radiotracer interference on the ureters. However, the
Fig. 4 Overview of patient images who were administered 2 MBq/kg who presented with common lesion locations: local recurrence (first row),
lymph node metastases (middle row) and bone metastases (last row), each presented as a MIP image (at T60, 3 min/bp) followed by axial images
(axis line displayed on MIP image) of all reconstructed time frames (T60, 1.5 and 3min/bp and T180, 1.5 and 3min/bp), and the high dose
CT image
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Fig. 5 Overview of patient images who were administered 4 MBq/kg who presented with common lesion locations: local recurrence (first row),
lymph node metastases (middle row) and bone metastases (last row), each presented as a MIP image (at T60, 3 min/bp) followed by axial images
(axis line displayed on MIP image) of all reconstructed time frames (T60, 1.5 and 3min/bp and T180, 1.5 and 3min/bp), and the high dose
CT image
Fig. 6 Comparison of interrater reliability kappa statistics between the original Phase 2 study and the additional Phase 2 study
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clinically relevant median difference of > 1 point was not
achieved. This means that a good image quality can be ob-
tained without the need for a diuretic which can cause
additional discomfort. Nonetheless, the addition of fur-
osemide can be beneficial for the detection of lymph
nodes in the prostate region or in proximity of the ureters
[22]. In this study protocol, a rather high dose of furosem-
ide (40mg) was administered 30min before the start of
the first PET/CT. It may be more appropriate to adminis-
ter a lower furosemide dose simultaneously with the ra-
diotracer administration for the comfort of the patient,
which is also recommended in the guidelines of EANM
and SNMMI for administration of 68Ga-PSMA [14].
PSMA expression is not specific to the prostate only;
physiological background uptake is seen in the kidneys,
bladder, intestines, and salivary glands as well as in
pathological conditions such as Paget’s bone disease and
neovasculature of several solid tumours such as high-
grade sarcomas [27–31]. Moreover, some prostatic ma-
lignant lesions exhibit minimal PSMA expression and
can be difficult to detect on PET [32]. Therefore, the
interrater reliability can be a useful parameter to assess
the clarity of 18F-PSMA-11 image interpretation and the
potential need for gaining experience in differentiating
prostate cancer lesions from benign focal uptake spots.
The interrater reliability was assessed twice. Initially, the
grade of agreement was determined in the original Phase
2 study within the 2MBq/kg group on T60, 3 min/bp
images. To see if a learning curve is applicable on the in-
terpretation of 18F-PSMA-11 images, the analysis was re-
peated on images of the additional Phase 2 study which
were carried out after all images from the initially in-
cluded patients were evaluated. It was considered valu-
able to evaluate the ability to assign the correct disease
status (local, locoregional, oligo- and polymetastatic dis-
ease) to each patient as this plays an important role in
determining the appropriate treatment. The κ statistic of
0.92 (95% CI, 0.76–1) suggested an almost perfect inter-
rater agreement in disease status and even increased to 1
(95% CI, 1–1) for the additional Phase 2. This would
make 18F-PSMA-11 an important tool for knowing the
disease status of the patient, which could influence the
treatment management plan. The forest plot in Fig. 6
clearly shows improvement in each category where κ
statistics were determined. This was in concordance with
the interobserver agreement study by Fendler et al. [27]
who also found that observers with less than 30 previous
PSMA image readings only showed moderate interrater
reliability contrary to more experienced observers who
achieved substantial to almost perfect agreement. Retro-
spectively, all observed lesions from the original Phase 2
were discussed with both observers. Of the seven bone
lesions on which the observers did not agree, two bone
lesions were determined suspicious and subjected to
follow-up while the other five bone lesions would not be
made suspicious again after the gained experience from
the trial.
This study was accompanied by some limitations.
Firstly, determining the optimal dosage was solely based
on a subjective scoring system. Furthermore, the PET
characteristics also play a role in scan parameters. This
was not accounted for as all scans were performed on
one PET system (GE Healthcare). Finally, further
optimization of image reconstruction parameters such as
number of subsets, number of iterations and post-
smoothing kernel should be investigated.
Conclusion
The best image quality was obtained by administration of
4.0 ± 0.4MBq/kg 18F-PSMA-11. However, preference will
be given to a dosage of 2.0 ± 0.2MBq/kg due to the small
difference in absolute score (max 1 point) and the ALARA
principle. PET acquisition should start 1 h post injection
with 3min per bed position acquisition time. Depending
on the medical history of the patient and the location of
metastatic lesions, the co-administration of a diuretic can
be useful. The increase of the κ value from 0.78 to 0.94
suggests that the interpretation of 18F-PSMA-11 is more
reliable after 40+ PSMA scan readings.
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